| Document and Entity Information - USD ($) | 12 Months Ended | ||
| Dec. 31, 2021 | Mar. 10, 2022 | Jun. 30, 2021 | |
| Cover [Abstract] | |||
| Document Type | 10-K/A | ||
| Amendment Flag | true | ||
| Amendment Description | On March 15, 2022, Inozyme Pharma, Inc. (the “Company”) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “Original Form 10-K”). This Amendment No. 1 (the “Amendment”) amends the Original Form 10-K solely to correct an administrative error in the content of Exhibit 23.1, Consent of Independent Registered Public Accounting Firm (the “Consent”), that resulted in an improperly worded auditor’s consent and omitted reference to a registration statement and related file number. A new Exhibit 23.1 with the appropriate corrections is filed as Exhibit 23.1 attached hereto. This Amendment speaks as of the original filing date and does not reflect events occurring after the filing of the Original Form 10-K. No revisions are being made to the Company’s financial statements or any other disclosure contained in the Original Form 10-K. This Amendment is an exhibit-only filing. Except for Exhibit 23.1, this Amendment does not otherwise update any exhibits as originally filed or previously amended. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), new certifications by the Company’s principal executive officer and principal financial officer are filed herewith as exhibits to this Amendment pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act. As no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. The Company is not including certifications pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) as no financial statements are being filed with this Amendment. | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Document Period End Date | Dec. 31, 2021 | ||
| Document Fiscal Year Focus | 2021 | ||
| Document Fiscal Period Focus | FY | ||
| Entity Registrant Name | INOZYME PHARMA, INC. | ||
| Entity Central Index Key | 0001693011 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity File Number | 001-39397 | ||
| Entity Tax Identification Number | 38-4024528 | ||
| Entity Address, Address Line One | 321 Summer Street | ||
| Entity Address, Address Line Two | Suite 400 | ||
| Entity Address, City or Town | Boston | ||
| Entity Address, State or Province | MA | ||
| Entity Address, Postal Zip Code | 02210 | ||
| City Area Code | 857 | ||
| Local Phone Number | 330-4340 | ||
| Title of 12(b) Security | Common stock, par value $0.0001 per share | ||
| Trading Symbol | INZY | ||
| Security Exchange Name | NASDAQ | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | true | ||
| Entity Ex Transition Period | false | ||
| ICFR Auditor Attestation Flag | false | ||
| Entity Shell Company | false | ||
| Entity Common Stock, Shares Outstanding | 23,672,566 | ||
| Entity Public Float | $ 245,164,789 | ||
| Documents Incorporated by Reference | The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended December 31, 2021. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K. | ||
| Auditor Firm ID | 42 | ||
| Auditor Location | Boston, Massachusetts | ||
| Auditor Name | Ernst & Young LLP |
